Nitazoxanide
Active ingredient: Nitazoxanide
In short: Diarrhea caused by Giardia lamblia or Cryptosporidium parvum: Nitazoxanide tablets (patients 12 years and older) are indicated for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum. Limitations of Use Nitazoxanide tablets have not been shown to be effective for the treatm
What is Nitazoxanide used for?
Diarrhea caused by Giardia lamblia or Cryptosporidium parvum:
Nitazoxanide tablets (patients 12 years and older) are indicated for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum.
Limitations of Use
Nitazoxanide tablets have not been shown to be effective for the treatment of diarrhea caused by Cryptosporidium parvum in HIV-infected or immunodeficient patients .
Nitazoxanide dosage
Important Administration Instructions for Pediatric Patients 11 years of Age or Younger:
Nitazoxanide tablets should not be administered to pediatric patients 11 years of age or younger because a single tablet contains a greater amount of nitazoxanide than the recommended dosing in this pediatric age group.
Table 1. Recommended Dosage
Age | Dosage | Duration
12 years and older | One nitazoxanide tablet (500 mg nitazoxanide) taken orally every 12 hours with food. | 3 days
How to take Nitazoxanide — instructions & advice from the label
Advise patients and parents/caregivers of pediatric patients taking nitazoxanide tablets of the following information:
Dosage and Administration:
Nitazoxanide tablets should be taken with food.
Drug-drug Interactions:
Avoid concurrent warfarin use.
All trademarks are the property of their respective owners.
Distributed by:
e5 Pharma, LLC
Boca Raton, FL 33432
Rev. 09/2025
IN135-00
Warnings & precautions
Do not take this medicine if: Nitazoxanide tablets and ALINIA for Oral Suspension are contraindicated in patients with a prior hypersensitivity to nitazoxanide or any other ingredient in the formulations.
Nitazoxanide side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of nitazoxanide was evaluated in 2177 HIV-uninfected subjects 12 months of age and older who received nitazoxanide tablets or ALINIA for Oral Suspension at the recommended dose for at least three days. In pooled controlled clinical trials involving 536 HIV-uninfected subjects treated with nitazoxanide tablets or ALINIA for Oral Suspension, the most common adverse reactions were abdominal pain, headache, chromaturia and nausea (≥2%).
Safety data were analyzed separately for 280 HIV-uninfected subjects ≥12 years of age receiving nitazoxanide at the recommended dose for at least three days in 5 placebo-controlled clinical trials and for 256 HIV-uninfected subjects 1 through 11 years of age in 7 controlled clinical trials. There were no differences between the adverse reactions reported for nitazoxanide-treated subjects based upon age.
The following adverse reactions have been identified during post approval use of nitazoxanide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. …
Drug interactions
Tizoxanide (the active metabolite of nitazoxanide) is highly bound to plasma protein (>99.9%). Therefore, monitor for adverse reactions when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin).
About this medicine
Nitazoxanide tablets contain the active ingredient, nitazoxanide, a synthetic antiprotozoal for oral administration. Nitazoxanide is a light yellow crystalline powder. It is poorly soluble in ethanol and practically insoluble in water. Chemically, nitazoxanide is 2-acetyloxy-N-(5-nitro-2-thiazolyl)benzamide. The molecular formula is C12H9N3O5S and the molecular weight is 307.3. The structural formula is:
Nitazoxanide tablets contain 500 mg of nitazoxanide and the following inactive ingredients: corn starch, sodium starch glycolate type A, sucrose, hydroxypropyl methylcellulose, talc, magnesium stearate, polyvinyl alcohol, titanium dioxide, D&C yellow #10 aluminum lake, lecithin (soy), xanthan gum, FD&C yellow #6 aluminum lake, FD&C blue #2 aluminum lake.
How it works: Nitazoxanide is an antiprotozoal . Absorption Single Dosing: Following oral administration of nitazoxanide tablets or ALINIA for Oral Suspension, the parent drug, nitazoxanide, is not detected in plasma. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 40a7cc30-76cd-49fe-965a-7823c4140d0f. Read the full official label on DailyMed.